Mostrar el registro sencillo del ítem
dc.contributor.author | Avendaño-Solà, C | |
dc.contributor.author | Ramos-Martínez, A | |
dc.contributor.author | Muñez-Rubio, E | |
dc.contributor.author | Ruiz-Antorán, Belén | |
dc.contributor.author | Malo de Molina, R | |
dc.contributor.author | Torres, F | |
dc.contributor.author | Fernández-Cruz, A | |
dc.contributor.author | Callejas-Díaz, A | |
dc.contributor.author | Calderón, J | |
dc.contributor.author | Payares-Herrera, C | |
dc.contributor.author | Salcedo, I | |
dc.contributor.author | Romera, I | |
dc.contributor.author | Lora-Tamay, J | |
dc.contributor.author | Mancheño-Losa, M | |
dc.contributor.author | Paciello, ML | |
dc.contributor.author | Villegas, C | |
dc.contributor.author | Estrada, V | |
dc.contributor.author | Saez-Serrano, I | |
dc.contributor.author | Porras-Leal, ML | |
dc.contributor.author | Jarilla-Fernández, MC | |
dc.contributor.author | Paño-Pardo, JR | |
dc.contributor.author | Moreno-Chulilla, JA | |
dc.contributor.author | Arrieta-Aldea, I | |
dc.contributor.author | Bosch, A | |
dc.contributor.author | Belhassen-García, Moncef | |
dc.contributor.author | López-Villar, O | |
dc.contributor.author | Ramos-Garrido, A | |
dc.contributor.author | Blanco, L | |
dc.contributor.author | Madrigal-Sánchez, ME | |
dc.contributor.author | Contreras, E | |
dc.contributor.author | Muñiz-Díaz, E | |
dc.contributor.author | Domingo-Morera, JM | |
dc.contributor.author | Casas Flecha, Inmaculada | |
dc.contributor.author | Bueno, JL | |
dc.contributor.author | Perez-Olmeda, Mayte | |
dc.contributor.author | García-Pérez, Javier | |
dc.contributor.author | Alcamí, José | |
dc.date.accessioned | 2020-09-14T07:34:32Z | |
dc.date.available | 2020-09-14T07:34:32Z | |
dc.date.issued | 2020-09-01 | |
dc.identifier.citation | medRxiv 2020.08.26.20182444. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/11007 | |
dc.description.abstract | Background: Passive immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19 for which evidence from controlled clinical trials is lacking. Methods: We conducted a multi-center, randomized clinical trial in patients hospitalized for COVID-19. All patients received standard of care treatment, including off-label use of marketed medicines, and were randomized 1:1 to receive one dose (250-300 mL) of CP from donors with IgG anti-SARS-CoV-2. The primary endpoint was the proportion of patients in categories 5, 6 or 7 of the COVID-19 ordinal scale at day 15. Results: The trial was stopped after first interim analysis due to the fall in recruitment related to pandemic control. With 81 patients randomized, there were no patients progressing to mechanical ventilation or death among the 38 patients assigned to receive plasma (0%) versus 6 out of 43 patients (14%) progressing in control arm. Mortality rates were 0% vs 9.3% at days 15 and 29 for the active and control groups, respectively. No significant differences were found in secondary endpoints. At inclusion, patients had a median time of 8 days (IQR, 6-9) of symptoms and 49,4% of them were positive for anti-SARS-CoV-2 IgG antibodies. Conclusions: Convalescent plasma could be superior to standard of care in avoiding progression to mechanical ventilation or death in hospitalized patients with COVID-19. The strong dependence of results on a limited number of events in the control group prevents drawing firm conclusions about CP efficacy from this trial. (Funded by Instituto de Salud Carlos III; NCT04345523). | es_ES |
dc.description.sponsorship | This research is funded by the Government of Spain, Ministry of Science and Innovation, Instituto de Salud Carlos III, grant number COV20/00072 (Royal Decree-Law 8/2020, of 17 March, on urgent extraordinary measures to deal with the economic and social impact of COVID-19), co-financed by the European Regional Development Fund (FEDER) ‘‘A way to make Europe’’ and supported by SCReN (Spanish Clinical Research Network), ISCIII, project PT17/0017/0009. Clinical trial insurance coverage was kindly donated by MARCH RS Correduría de Seguros y Reaseguros. Mikel Mancheño-Losa holds a "Río Hortega" research contract (expte. CM19/00226 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | medRxiv | |
dc.type.hasVersion | AM | es_ES |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial | es_ES |
dc.type | preprint | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.identifier.doi | 10.1101/2020.08.26.20182444 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.description.peerreviewed | No | es_ES |
dc.relation.publisherversion | https://doi.org/10.1101/2020.08.26.20182444 | es_ES |
dc.identifier.journal | medRxiv | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/COV20/00072 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/PT17/0017/0009 | es_ES |
dc.rights.accessRights | open access | es_ES |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
IIS Aragón - Instituto de Investigación Sanitaria Aragón (Aragón)
-
Centro Nacional de Microbiología (CNM)
-
i+12 - Instituto de Investigación Hospital 12 de Octubre (Madrid)
-
IBSAL - Instituto de Investigación Biómedica de Salamanca (Castilla y León)
-
IDIPHIM - Instituto de Investigación Sanitaria Puerta de Hierro (Madrid)